FindTrial
Sign In

gp160 Vaccine (MicroGeneSys)

BIOLOGICAL13 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb

Conditions

HIV InfectionsHIV SeronegativityPregnancy

Phase 1

Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
CompletedNCT00000630
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1992-12-31Target: 35Updated: 2021-10-27
A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
CompletedNCT00000631
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1992-12-31Target: 13Updated: 2021-11-02
A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells
CompletedNCT00000667
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1993-07-31Target: 20Updated: 2021-11-03
A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
CompletedNCT00000762
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-02-29Target: 72Updated: 2021-11-03
Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
CompletedNCT00000977
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1993-05-31Target: 52Updated: 2021-11-04
A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
CompletedNCT00000683
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1993-06-30Target: 54Updated: 2021-11-02
A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
CompletedNCT00000956
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1993-03-31Target: 25Updated: 2021-11-04
A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
CompletedNCT00000745
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1991-05-31Target: 72Updated: 2021-11-04
A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
CompletedNCT00000782
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-10-31Target: 50Updated: 2021-11-04
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
CompletedNCT00002261
Bristol-Myers SquibbHIV Infections
Updated: 2007-09-26
A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
CompletedNCT00000757
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1992-10-31Target: 30Updated: 2021-11-04
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
CompletedNCT00000746
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1994-07-31Target: 56Updated: 2021-11-04
Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
CompletedNCT00000777
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity, Pregnancy
End: 1998-07-31Target: 24Updated: 2021-10-28